Across TCGA pan-cancer cohorts, ZNF667 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZNF667 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ZNF667 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ZNF667 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCEC, LUAD, and LIHC are the cancer types where ZNF667 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	1.000	0.302	.004	36	view →
LUAD	DFS	Median	IV	0.045	0.717	<.001	12	view →
LIHC	OS	Median	All	0.419	0.778	.008	9	view →
LUSC	OS	Median	All	0.463	0.825	.013	6	view →
STAD	DFS	Median	All	0.782	0.379	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ZNF667 tumor-vs-normal RNA expression · all ZNF667 data types